Overview

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

Status:
Completed
Trial end date:
2017-05-18
Target enrollment:
Participant gender:
Summary
Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at Tyler
Collaborator:
Abbott
Treatments:
Clarithromycin